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Abstract
Efficient targeted delivery of anticancer agents to TNBC cells remains one of the greatest challenges to developing therapies. The 
lack of tumor-specific markers, aggressive nature of the tumor, and unique propensity to recur and metastasize make TNBC 
tumors more difficult to treat than other subtypes. We propose to exploit natural ability of macrophages to target cancer cells by 
means of extracellular vesicles (EVs) as drug delivery vehicles for chemotherapeutic agents, paclitaxel (PTX) and doxorubicin 
(Dox). We demonstrated earlier that macrophage-derived EVs loaded with PTX (EV-PTX) and Dox (EV-Dox) target cancer cells 
and exhibited high anticancer efficacy in a mouse model of pulmonary metastases. Herein, we report a manufacture and 
characterization of novel EV-based drug formulations using different loading procedures that were optimized by varying pH, 
temperature, and sonication conditions. Selected EV-based formulations showed a high drug loading, efficient accumulation in 
TNBC cells in vitro, and pronounced anti-proliferation effect. Drug-loaded EVs target TNBC in vivo, including the orthotopic 
mouse T11 tumors in immune competent BALB/C mice, and human MDA-MB-231 tumors in athymic nu/nu mice, and 
abolished tumor growth. Overall, EV-based formulations can provide a novel solution to a currently unmet clinical need and 
reduce the morbidity and mortality of TNBC patients.
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Introduction
TNBC is a highly aggressive and metastatic cancer that is
characterized by minimal estrogen and progesterone recep-
tors, as well as nominal human epidermal growth factor re-
ceptor 2 (HER2) expression (Mersin, Yildirim et al. 2008).
The development, progression, and metastasis of TNBC are
the leading cause among female mortality. The current
standard of care revolves around the use of various neoadju-
vant chemotherapeutics (Ren, Hao et al. 2019), including
anthracyclines, taxanes, and platinum agents (Walsh,
Shalaby et al. 2019), as well as poly(ADP-ribose) polymer-
ases (PARP) inhibitors (Zhou, Ji et al. 2016), and immune
checkpoint inhibitors (Cyprian, Akhtar et al. 2019).
Chemotherapy remains the only adjuvant treatment for
TNBC, but responses are usually brief and associated with
progressive resistance, short survival, and systemic toxicities.
Thus, the development of new effective delivery approaches
and in particular, more effective chemotherapies, determines
translational success of these antineoplastic drugs for TNBC.
A large proportion of chemotherapeutics have low aqueous
solubility, consequently requiring the use of specialized
nanosized delivery vehicles (e.g. micelles, liposomes, poly-
meric nanoparticles, or other types of nanoparticles) for par-
enteral administration. Much effort has been dedicated to the
development of drug nanoformulations targeted to tumors, but
these efforts have been met with limited success (Chandolu
and Dass 2013). Nanoparticles are promising platforms for
treating cancer, but mainstream nanoparticles target tumors
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passively through the enhanced permeability and retention
(EPR) effect, hence their accumulation in tumors is not effi-
cient (typically <5% of the injected dose) and greatly affected
by the tumor type and stage. A fundamental roadblock in the
use of drug nanoformulations for many diseases is the
opsonization of drug-loaded nanoparticles in the bloodstream
and rapid drug clearance by mononuclear phagocyte system
(MPS) (Peng, Zhang et al. 2013). To solve this problem, drug-
loaded nanocarriers were decorated with a polyethylene gly-
col (PEG) corona to avoid this clearance, but along with the
decreasing drug uptake by monocytes, the PEGylation con-
currently reduced the interaction with target cancer cells, thus
decreasing drugs therapeutic efficiency (Beckman, Minor
et al. 1988, Yoshida, Burton et al. 1992, Veronese, Caliceti
et al. 2002). Furthermore, as many as 30% of healthy recipi-
ents have already developed immune response to the PEG
corona that significantly increases clearance of PEGylated
drug nanocarriers (Dams, Laverman et al. 2000, Maeda et al.
2003, Masuda et al. 2003, Kashima et al. 2008). In this regard,
active cancer-targeting moieties, such as antibodies and spe-
cific peptides, have been added to the drug nanoformulations,
however the relatively short circulation time and the complex-
ity of producing such carriers hinder their application. This
approach is especially challenging taking into account the
absence of specific markers on TNBC tumors. Finally, devel-
opment of chronic autoimmune diseases such as rheumatoid
arthritis was reported in a response to administration of differ-
ent types of nanoparticles (Farhat, Silva et al. 2011,
Mohamed, Verma et al. 2012). Therefore, engineering new
clinically applicable drug delivery systems for TNBC therapy
is of particular importance.
Recently, EVs have begun to be explored for use as
drug delivery vehicles for non-native therapeutics such
as nucleic acids (Alvarez-Erviti, Seow et al. 2011, Pan
et al., 2012, Wahlgren et al., 2012, Shtam et al., 2013,
Chen et al., 2014, Johnsen et al., 2014, Lamichhane
et al., 2015, Aryani and Denecke 2016), therapeutic
proteins (Haney et al., 2015), and small molecule drugs
(Sun et al., 2010, Zhuang et al., 2011, Johnsen et al.,
2014, Kalani et al., 2014, Tian et al., 2014, Agrawal
et al., 2017, Schindler et al. 2019), as well as imaging
agents (Gorgens et al. 2019). In fact, EVs naturally
function as intracellular messengers, carrying RNAs
and proteins between the cells (Mathivanan et al.
2010, Raposo and Stoorvogel 2013). Thus, EVs also
exhibit increased stability in the blood that allows them
to travel long distances within the body under both
physiological and pathological conditions (Jiang and
Gao 2017). The membranotropic nature of EVs sug-
gests that these drug carriers will be able fuse with
cancer cell’s membranes and deliver their toxic pay-
load. This process is facilitated by the expression of
various adhesive proteins (tetraspanins and integrins)
on the surface of EVs (Mulcahy et al. 2014). Of note,
EVs are able to avoid one of the main hurdles for
nanoformulations, sequestration in endosomes, and de-
liver their intraluminal cargo into the cytosol of target
cancer cells (Montecalvo et al. 2012, Schindler et al.
2019). In addition, allogenic EVs have an immune
privileged status, which allows for decreased drug
clearance by MPS (Ha et al. 2016). Specifically,
immunocytes-derived EVs are known to express CD47
receptor (Kaur et al. 2014), which interacts with signal
regulatory protein α (SIRPα), to produce a “don’t eat
me” signal in phagocytes (Gardai et al. 2005, Long
and Beatty 2013). Finally, EVs nanocarriers were
shown to reduce unwanted side effects, including
cardiotoxicity (Schindler et al. 2019), hepatotoxicity
and immunogenicity (Saleh et al. 2019). For example,
it was reported that in contrast to other delivery
methods for doxorubicin, EVs do not accumulate in
the heart, thereby providing potential for limiting the
cardiac side effects and improved therapeutic index
(Schindler et al. 2019). These unique features make
EVs an attractive option for use as drug delivery vehi-
cles for TNBC treatment. More information can be
found in recent excellent review articles (Maas et al.
2017, Armstrong and Stevens 2018, Liu and Su 2019,
Pullan et al. 2019, Zhang et al. 2019).
One of the major impediments for using EVs as drug de-
livery vehicles is their efficient loading with therapeutic
agents without significant alterations of the membrane struc-
ture and surface proteins. We reported earlier that
macrophage-derived EVs can be loaded with low molecular
chemotherapeutics, such as PTX and Dox (Kim, Haney et al.
2016), or therapeutic proteins, such as catalase (Haney et al.
2015) and brain-derived neurotrophic factor (BDNF) (Yuan
et al. 2017), and then utilized as drug delivery vehicles to
tumors, or/and inflamed brain tissues. Various methods of
drug incorporation into EVs nanocarriers were utilized, in-
cluding electroporation, extrusion, and saponin perme-
abilization of EVs membranes, as well as sonication and
freeze-thaw cycles.
Regarding targeted drug delivery, macrophage-derived
EVs possess an extraordinary ability to interact with and ac-
cumulate in cancer cells. We demonstrated earlier several-fold
increases in EVs accumulation in murine Lewis Lung
Carcinoma cells (3LL-M27) compared to synthetic
nanocarriers, polymer-based nanoparticles or liposomes
(Kim, Haney et al. 2016). Important, macrophage-derived
EVs target cancer cells, as well as inflamed tissues, through
LFA-1 protein expressed on their surface and intercellular
adhesion molecule-1 (ICAM-1) that is overexpressed in the
most cancer cells (Rufino-Ramos et al. 2017, Yuan et al. 2017,
Kim, Haney et al. 2018) and specifically in TNBC cells (Guo
et al. 2014). Therefore, the inflammation developed upon
tumor growth and overexpression of ICAM-1 on tumor endo-
thelium (Guo et al. 2014) may promote targeted delivery of
anticancer agents to TNBC tumors by macrophage-derived
EVs. Based on these findings, we hypothesized that biomi-
metic EV-based drug delivery system will be capable of rec-
ognizing and targeting TNBC, and as such, deliver incorpo-
rated chemotherapeutic to the TNBC tumors.
Here we report the development of new EV-based formu-
lations for TNBC therapy. Dox and PTX were selected as
representatives of two types of potent chemotherapeutics that
have highly hydrophilic or hydrophobic properties, respec-
tively. Several methods for loading were tested, including
drug incorporation into naïve EVs followed by their isolation
frommacrophage conditioned media, or through parental cells
during EVs formation. A robust accumulation, and nearly
complete co-localization of systemically administered EVs
with TNBC cells was demonstrated in mouse orthotopic tu-
mor models. Furthermore, a significant inhibition of tumor
growth was observed in both the orthotopic T11 tumors in
immune competent BALB/C mice, and human MDA-MB-
231 tumors in xenograft model in athymic nu/nu mice. We
posit that EV-based formulations have a tremendous potential
for efficient drug transport capable of overcoming various
biological barriers. These formulations represent the next gen-
eration of drug delivery systems for precision medicine that




PTX and Dox was purchased from LC Laboratories (Woburn,
MA, USA). Lipophilic fluorescent dyes, 1,1′-dioctadecyl-
3,3,3′,3′-tetramethylindo-carbocyanine perchlorate (DIL),
and were purchased from Invitrogen (Carlsbad, CA, USA).
4′,6-diamidino-2-phenylindole dihydrochloride (DAPI), and
Triton X-100 were obtained from Sigma-Aldrich (St. Louis,
MO, USA). Cell culture medium and fetal bovine serum
(FBS) were purchased from Gibco Life Technologies,
(Grand Island, NY, USA). Fluorescent polystyrene nanoparti-
cles (Fluoro-Max G100), as well as Oregon Green™ 488 pac-
litaxel were obtained from Thermo Fisher Scientific
(Waltham, MA, USA).
Cells
Murine TNBC cell line T11, and the human breast cancer cell
lines MDA-MB-231 were obtained from the American Type
Culture Collection (ATCC, Manassas, Virginia, USA), and
grown in alpha Minimum Essential Medium (alpha-MEM,
Mediatech, Tewksbury, MA, USA) containing 10% FBS,
supplemented with 0.1 mM nonessential amino acids, 1 mM
sodium pyruvate and 0.01 mg/mL bovine insulin (CellGro,
Newington, USA), 10 mM HEPES, 50 μg/ml gentamycin
(Invitrogen, Carlsbad, CA, USA). RAW 264.7 macrophages
were purchased from ATCC and cultured in Dulbecco’s mod-
ified Eagle’s medium (DMEM) high glucose (Gibco) supple-
mented with 10% heat-inactivated fetal bovine serum (FBS),
1% penicillin and streptomycin. All cells were cultured in a
humidified atmosphere at 37 °C and 5% CO2.
Animals
Athymic nu/nu mice and Balb/C mice (6- to 8-weeks-old fe-
males) were obtained from Charles River Laboratories
(Durham, NC, USA) and used for in vivo tumor assays. The
animals were kept five per cage with an air filter cover under
light- (12-h light/dark cycle) and temperature-controlled (22
± 1o C) environment. Food and water were given ad libitum.
All manipulations with the animals were performed under a
sterilized laminar hood. All experiments were carried out with
approval of Institutional Animal Care and Use Committees
(IACUC) of University of North Carolina at Chapel Hill, in
compliance with the US Public Health Service guidelines for
the care and use of animals in research.
Isolation and Characterization of EVs
EVs were harvested from the conditioned media of
RAW 264.7 macrophages seeded into Bioreactor (3.6 ×
108 cells/flask) and cultured in EV-depleted media for
2 days using gradient centrifugation and described in
(Haney et al. 2015). In brief, the culture supernatants
were cleared of cell debris and large vesicles by sequen-
tial centrifugation at 300 g for 10 min, 1000 g for
20 min, and 10,000 g for 30 min, followed by filtration
using 0.2 μm syringe filters. Then, the cleared sample
was spun at 100,000 g for one hour to pellet the EVs,
and supernatant was collected. The collected EVs (1011–
1012 EVs/flask) were washed twice with phosphate buff-
er solution (PBS). To avoid contamination by the FBS-
derived EVs, FBS was spun at 100,000 g for 2 h to
remove EVs before the experiment. The recovery of
EVs was estimated by measuring the protein concentra-
tion using the Bradford assay and by Nanoparticle
Tracking Analysis (NTA). The obtained EV fraction
was re-suspended in PBS (500 μl, 1 mg/mL total pro-
tein), and characterized by western blot (Wes),
Nanoparticle Tracking Analysis (NTA), Dynamic Light
Scattering (DLS), Transmission Electron Microscopy
(TEM) as described previously (Haney et al. 2015).
EVs suspension was stored in aliquots at -80o C before
use.
Drug Loading into EVs
Dox and PTX have different solubility in water solutions,
therefore two separate types of methods for loading into EVs
were carried out, Type I for Dox, and Type II for PTX.
Type I. In case of hydrophilic Dox, five different ap-
proaches were utilized: A stock solution of Dox (1 mg/
mL) in 100 μL water was added to 100 μL EVs (4 × 1012
particles/mL) and incubated at RT for 2 h (1), or sonicated
in water bath for 30 min and then incubated at RT for
1.5 h (2). The same mixture EVs and Dox was prepared
in phosphate buffer (pH 8.0), incubated for 2 h at RT (3),
or sonicated in water bath for 30 min and then incubated
at RT for 1.5 h (4). Followed the incubation the mixtures
were supplemented with 350 μL HEPES buffer (pH 7.4),
and the excess free drug was separated from EV-Dox by
size exclusion chromatography using a NAP-10
S e p h a d e x G 2 5 c o l um n (GE H e a l t h c a r e ,
Buckinghamshire, UK). Finally, parental macrophages
grown on 75 T flask were supplemented with 10 mL
Dox solution in full media (30 μg/mL) and incubated
for 4 h at 37 °C. Followed incubation, culture media
was collected and EVs were isolated as described above
(5). The loading efficiency of Dox in EVs formulation
was determined by Dox fluorescence.
Type II. In case of hydrophobic PTX, another four differ-
ent approaches were utilized. (1) PTX stock solution
(1 mg/mL) in EtOH (10 μL) was placed into Eppendorf
tube and EtOH was evaporated under nitrogen flow to
form a thin film. Lyophilized EVs (3 × 1011 particles/
100 μL) re-suspended in 30 μL water were added to the
Eppendorf with PTX film and incubated for 1 h at 37 °C.
(2) PTX stock solution (1 mg/mL) in ethanol (EtOH,
10 μL) was added to lyophilized EVs (3 × 1011 parti-
cles/100 μL) re-suspended in 30 μL water, and incubated
for 1 h at 37 °C. (3) PTX stock solution (1 mg/mL) in
EtOH (100 μL) was supplemented with 300 μL EVs in
PBS (3 × 1011 particles/mL), and sonicated using probe
sonicator (3 s “on”/3 s “off” at 100Wamplitude on ice, ×
12 cycles). (4) PTX stock solution (1 mg/mL) in EtOH
(100 μL) was supplemented with 300 μL EVs in PBS
(3 × 1011 particles/mL), and sonicated using probe
sonicator (3 s “on”/3 s “off” at 100 W amplitude at RT,
10 min cooling × 12 cycles). After sonication, EV-PTX
solution were incubated for 1 h at 37 °C to allow for
recovery of EVs membrane. In all cases, the excess of
free drug was separated from EV-PTX by size exclusion
chromatography using a NAP-10 Sephadex G25 column
(GE Healthcare, Buckinghamshire, UK). The amount of
PTX loaded into EVs was determined by two different
methods: (i) HPLC on a Nucleosil C18 reverse phase
column with a flow rate of 1 mL/min, 55% / 45%
acetonitrile/water mobile phase, at 30 °C as described in
(Kim, Haney et al. 2018); and (ii) by fluorescence using
Oregon Green PTX (ThermoFisher Scientific, Waltham,
MA, USA). The fluorescense was measured at wlex =
495 nm, and wlem = 525 nm. The size and concentration
of EV-based drug formulations was characterized by
NTA.
Transmission Electron Microscopy (TEM)
A drop of isolated EVs fraction with incorporated drugs in
PBS was placed on Formvar®-coated copper grid (150 mesh,
Ted Pella Inc., Redding, CA). The dried grid containing EVs
were stained with vanadyl sulfate and visualized using a
Philips 201 transmission electron microscope (Philips/FEI
Inc., Briarcliff Manor, NY).
Preparation and Loading of Liposomes with Dox
or PTX
Dox was loaded into liposomes using extrusion procedure as
describer previously (Haney et al. 2015). Liposomes were
prepared by reverse phase evaporation method. Briefly,
2 mg of phospholipids (phosphatidylcholine:PEG-PE (1,2-
d i s t ea roy l - sn -g l yce ro -3 -phosphoe thano l am ine -
N-[methoxy(polyethylene glycol)-2000] 95:5 wt/wt), were
dissolved in 6 mL of chloroform: diisopropyl ether 1:1 mix-
ture. PEG-PE was added for stabilization of liposomes. Then
PTX in EtOH (10 μL) and 1 ml PBS were added to the mix-
ture. Mixture was intensively vortexed and bath sonicated to
form stable emulsion. Organic solvents were evaporated on
rotary evaporator forming the liposome aqueous dispersion.
200–250 μl ofMillipore water can be added at this point to the
mixture in case some part of water was also evaporated.
Evaporation was continued to get almost clear dispersion.
Then volume was adjusted to 1 mL by addition of small
amount of water. Dispersion was vortexed and bath sonicated
to get clear solution. Liposomes were sequentially extruded 21
times through 200 nm polycarbonate filters using a hand ex-
truder (Avanti) at 60 °C. In case of Dox-loaded liposomes, a
stock solution of Dox (pH 8.0) was added before the extrusion
to load into liposomes. Liposomes were purified by PEG pre-
cipitation remove not encapsulated drug.
Manufacture Fluorescently-Labeled Nanocarriers
A suspension of EVs in PBS (1 mL) was supplemented with
1 mM DID solution (40 μL) and incubated at 37C for 30 min
in dark. In parallel, 1 mL liposomal suspension was supple-
mented with 40 μL DID (1 mM solution in DMSO), and
incubated for 30 min at 37C. DID-labeled nanocarriers were
purified from non-incorporated dye by size-exclusion
chromatography on Sepharose CL-4B at RT. Fluorescence
levels were measured at wlex = 644, wlcut off
= 665, wlem =
675. The size of the obtained DID-nanocarriers was measured
by NTA (for liposomes: Size min = 111 ± 2.4 nm, Size mode
98 ± 4.7, conc. 9.2 × 1012 particles/mL; for EVs: Size min =
110.3 ± 1.6 nm, Size mode 100.2 ± 3.4, conc. 8.2 × 1012 par-
ticles/mL).
Accumulation of Drug-Loaded into EVs in Breast
Cancer Cells In Vitro
Effect of EVs nanocarriers on accumulation of Dox and PTX
incorporated into EVs was investigated in MDA-MB-231
cancer cells in comparison with liposomal Dox or PTX
(Lipo-Dox and Lipo-PTX, respectively). For this purpose, cell
monolayers grown on 96-weel plates were incubated with
drug-loaded EVs or liposomes (7 × 109 particles/ml) at
37 °C and 5% CO2 for 4 h. Fluorescently-labeled Oregon
Green ™ 488 PTX was used for these studies. Followed in-
cubation, the media was removed, and cells were washed 3x
with PBS. Liposomes were loaded with the drug using extrud-
er as described above. The cell suspension was then lysed and
analyzed for drug content by fluorescence.
In a parallel experiment, MDA-MB-231 cell monolayers
grown in chamber slides, were incubated with drug-loaded
EVs or liposomes (7 × 109 particles/ml) at 37 °C for 4 h.
Dox or fluorescently-labeled Oregon Green ™ 488 PTX
was used for these studies. Following incubation, cells were
washed 3X with PBS, and mounted on slides with DAPI nu-
clei staining. The images of the cells were examined by a
confocal fluorescence microscopic system ACAS-570 and
corresponding filter set.
In Vitro Cytotoxicity Assay
The in vitro antitumor efficacy of EV-PTX and EV-Dox was
assessed using a standard MTT (3-(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyl-2-H-tetrazoliumbromide) assay with three can-
cer cell lines, and compared to Taxol as described earlier
(Batrakova et al. 2010). Briefly, TNBC cells (MDA-MB-
231) were seeded at 5000 cells/well in 100 μL of media in
96-well plates overnight. Various concentrations of differed
EV-PTX formulations, or Taxol were added to cancer cells
for 48 h at 37C, 5% CO2. Following the incubation, the cells
were washed and incubated with MTT reagent as described in
(Batrakova et al. 2006). The cytotoxic activity of PTX was
then evaluated using a standard MTT assay (Ferrari et al.
1990). The absorbance at 570 nm was measured using a
Shimadzu RF5000 fluorescent spectrophotometer. The sur-
vival values were determined in relation to control cells cul-
tured in drug-free media. IC50 values for the potency of EV-
based and liposomal drug formulations were obtained using
GraphPadPrism. All experiments were repeated at least three
times. SEM values were less than 10%.
Production of a Lentiviral Vector (LV)
and Transduction of T11 Cells
To utilize bioluminescence and fluorescence imaging, T11
cells were transduced with lentiviral vectors encoding
mCherry (GBM8FlmC) and firefly luciferase (FLuc) fusion
protein. The viral construct also encoded for a puromycin
resistance gene downstream of mCherry, which was intro-
duced to enable for selection of nearly 100% positively trans-
duced cells. Lentiviral vector was created by PCR amplifica-
tion of the cDNA sequences for mCherry and FLuc from
pEmCherry (Clontech) and pcDNA-Luciferase (Addgene)
with restriction enzyme sequences that were engineered into
the primers. To create the final constructs, mCherry was
digested with BamHI/EcoV and FLuc was digested with
EcoV/XhoI. The digested fragments were ligated into the
BamHI/XhoI digested pTK402 LV transfer vector (a kind gift
from Dr. Tal Kafri, The University of North Carolina at
Chapel Hill). LV-mCherryFLuc viral vectors were packaged
in T11 cells by transient transfection using the psPAX2 and
pMD2.G (Addgene) packaging plasmids and following previ-
ously described protocols (Sena-Esteves et al. 2004). A robust
expression of both the fluorescent and bioluminescent
markers was observed, and no difference in proliferation
was detected between modified and unmodified cells. These
cells (8FlmC-FLuc-T11) were used for biodistribution and
therapeutic efficacy studies.
Orthotopic TNBC Mouse Model
To establish orthotopic TNBC mouse model, MDA-MB-231
cells (100,000 cells/50 μL/mouse) were implanted to the
mammary fat pad (left side) in nude/nude mice (n = 5–7
mice/group) as described above. Cells at a dose of 100,000
in culture medium (50 μL) were mixed with a 1:1 ratio of
matrigel (BD Biosciences) and then implanted to the mamma-
ry fat pad. When the tumor size reached a size of about
50 mm3, mice were randomly divided into groups and i.v.
injected with different formulations of Dox or PTX or
fluorescently-labeled nanocarriers.
Biodistribution of EVs and Cancer Cells Targeting
in Mice with TNBC Tumors
Balb/C mice (n = 4) were inoculated orthotopically with
8FlmC-FLuc-T11 cells (0.8 × 106 cells/mouse in 50 μL of
matrigel) and solid tumor were allowed to establish for 10–
12 days. Twelve days following cancer cells i.v. injection,
DID-labeled EVs isolated from autologous macrophages were
administered via tail vein (i.v.), or intratumoral (i.t.), or
intraperitoneal (i.p.) route in a dose 1011 particles/100 μl to
mice with established T11 solid tumors. Twenty-four hours
later, mice were sacrificed, perfused, tumors were extracted
and sectioned on a microtome at a thickness of 20 μm; nuclei
were stained with DAPI (300 mM, 5 min). The images of
tumor sections were examined by a confocal fluorescence
microscopic system ACAS-570 and corresponding filter set
and processed using ImageJ software.
Therapeutic Efficacy of EV-PTX against TNBC In Vivo
The antineoplastic effects of EV-PTX were evaluated in an
orthotopic mouse models of TNBC including T11 tumors in
immune competent BALB/C mice, and human MDA-MB-
231 tumors in athymic nu/nu mice. For this purpose, mice
with established TNBC solid tumors as described above were
i.v. injected with EV-Dox (2.5 mg/kg) or EV-PTX (0.5 mg/kg)
in 109 EVs/100 μl/mouse. The same doses of commercially
available drug formulation (Doxil or Taxol), or saline were
administered into control groups (N = 7). The drug formula-
tions were given intravenously (i.v.) in a volume of 10 mL/kg
on days 1, 4, 7, 10, and 14 after random group assignment.
Tumor length (L) and width (W) were measured, and tumor
weight (WR) was calculated twice a week as follows:
WR ¼ 1=2 x L x W2
The data were expressed in relative weight (RW) calculated
using the formula:
RW ¼ Wi=Wo;
where Wo is the mean tumor weight at the beginning of treat-
ment andWi is the mean tumor weight at any subsequent time
point. The rate of tumor inhibition was determined on day 18
after group assignment for T11 tumors and day 64 for MDA-
MB-231 tumors using the following formula:
TI %ð Þ ¼ 1−RWt=RWcð Þ x 100%;
where RWt and RWc are relative weights in the treated and
control groups, respectively. Both the RW and TI indexes were
considered not measurable if at least one animal in the treated
group died by the day of measurement (on 19 day for T11
bearing mice, and on 65 day for MDA-MB-231 bearing
mice).
Statistical Analysis
For the all experiments, data are presented as the mean
± S.E.M. Tests for significant differences between the
groups were performed using a t-test or one-way
ANOVA with multiple comparisons (Fisher’s pairwise
comparisons) using GraphPad Prism 5.0 (GraphPad
software, San Diego, CA). A minimum p value of
0.05 was chosen as the significance level.
Results
Manufacture and Characterization of EV-Dox
and EV-PTX
Two chemotherapeutic agents, Dox and PTX, were selected as
representatives of hydrophilic and hydrophobic small mole-
cule antineoplastic agents, respectively. Based on their solu-
bility in water solutions, different approaches for incorpora-
tion these drugs into macrophage-derived EVs were utilized.
EV-Dox formulations were prepared through (i) drug
incorporation into naïve EVs isolated from parental
macrophages using mild sonication in water bath, or
incubation at room temperature (RT); or (ii) incubation
parental macrophages with the drug followed by EVs
isolation from the cells conditioned media. Regarding
the first approach, we reported earlier that the efficient
drug loading can be achieved, when EVs subjected to
sonication treatment in the presence of the drug (Kim,
Haney et al. 2016). Herein, we utilized this approach
with additional pH manipulations: at pH 7.4 (physiolog-
ical conditions) and pH 8.0 (near the pI for Dox that is
8.4). As expected, EVs sonication in the presence of
Dox increased drug incorporation into EV nanocarriers
(Fig. 1 a, black bars) compared to simple drug co-
incubation with EVs at RT (Fig. 1 a, white bars). In
addition, loading at pH 8.0 further increased amount
of the drug loaded into EVs compared to loading at
physiological pH 7.4 (Fig. 1 a). We hypothesized that
partial discharge of Dox molecule might facilitate its
diffusion across tight lipid bilayers of EVs membranes
and therefore increase Dox loading. Of note, complete
discharging of Dox molecule at pI 8.4 resulted in drug
precipitation; therefore, we did not utilize these condi-
tions in further experiments. Next, drug loading through
parental macrophages also provided a considerable
amount of Dox incorporated into EVs (Fig. 1 a).
Nevertheless, the amount of Dox loaded through paren-
tal cells was significantly lesser than the drug incorpo-
rated into EVs by co-incubation and/or sonication. Of
note, the size of EV-Dox nanoformulations was slightly
increased compared to naïve EVs as detected by NTA
(Fig. 1 b), especially upon sonication at pH 8.0, and
loading through parental cells.
Next, PTX is a highly hydrophobic drug; therefore, it was
first diluted in ethanol and then incorporated into EVs through
incubation at RT, or sonication procedures (Fig. 1 c). For the
loading by incubation method, the drug was introduced using
two ways: (i) PTX ethanol solution was first added to the tube
and ethanol was evaporated to obtain a thin film, and then EVs
suspension was added to the PTX film; or (ii) PTX ethanol
solution was directly added to the EVs suspension. The latter
approach resulted in higher drug loading into EVs compared
to thin film of PTX supplemented with EVs nanocarriers (Fig.
1 c). Furthermore, as expected, sonication of EVs in the pres-
ence of PTX provided the most efficient drug incorporation
into EVs. Interesting, keeping the mixture on ice during the
sonication procedure significantly reduced PTX loading com-
pared to the mixture cooling only during the “off” time soni-
cation periods. We hypothesized that elevated temperature
during sonication might make EVs membranes less rigid,
and therefore, increase their permeability for the drug. The
obtained EV-PTX formulations were characterized by NTA
(Fig. 1 d). Similar to EV-Dox (Fig. 1 b), NTA recorded slight
increases in size of EV-PTX nanoformulations upon all load-
ing procedures, especially for the sonication on ice.
TEM studies confirmed spherical morphology and rel-
atively uniform size distribution of the drug-loaded EV-
Dox and EV-PTX (Fig. 1 e and Fig. 1 f, respectively).
Finally, according to Western blot analysis, sonicated
EVs retained their EV-specific proteins, CD63, TSG101,
and HSP90 (Figure S1 A), although at lesser levels than
control naïve EVs (Figure S1 B).
Accumulation of EV-Dox and EV-PTX in Target Cancer
Cells In Vitro
The efficient delivery of the drug payload into target cells
is crucial for the therapeutic efficacy of EVs formulations.
To have a fair comparison with EVs nanocarriers, we uti-
lized liposomes that closely mimic natural cellular mem-
branes. Specifically, cellular membranes contain abundant


























































Fig. 1 Characterization of EVs-based drug formulations. a: Dox was
loaded into naïve EVs at different pH (7.4 and 8.0, 2 h-incubation) or
through parental macrophages (pH 7.4, 4 h-incubation). c: PTX was
loaded into naïve EVs during incubation when drug was introduced as
a thin film, or in the bulk solution; or sonication by probe sonicator (3 s
“on”/3 s “off” at 100 W amplitude, 10 min cooling × 36 cycles) with or
without cooling during sonication. a: Decreasing the overall charge of
Dox molecule at pH 8.0 resulted in greater drug incorporation into EVs.
c: Sonication at RT with periods of cooling down provided the most
efficient loading into EVs, compared to sonication on ice at all times.
Loading procedures slightly increased the size of EVs-based formulations
for EV-Dox (b) and EV-PTX (d). TEM images revealed spherical shape
and uniform size distribution of EV-Dox (e) and EV-PTX (f). *p < 0.05,
**p < 0.005, N = 6. The bar = 200 nm
2010). Therefore, we used a mixture of phosphatidylcho-
line and PEG-PE to resemble membrane bilayer. Herein,
we compared accumulation of drugs incorporated into
EVs against drugs loaded into liposomes, which also con-
sist of lipid bilayers, ((phosphatidylcholine:PEG-PE (1,2-
d i s t ea roy l - sn -g l yce ro -3 -phosphoe thano l am ine -
N-[methoxy(polyethylene glycol)-2000] 95:5 wt/wt), but
lack surface adhesion proteins, integrins and tetraspanins,
that are present in EVs (Figure 1S). As expected, the
chemotherapeutics loaded into EVs were taken up at
much greater quantities by MDA-MB-231 cells than cor-
responding drugs loaded into synthetic nanocarriers, lipo-
somes (ca. 150 times greater - for Dox, and 90 times - for
PTX, Fig. 2 a). This is consistent with our previous re-
ports, where we demonstrated that accumulation levels of
fluorescently-labelled EVs nanocarriers in cancer 3LL-
M27 cells was substantially greater then accumulation of
liposomes or polysterol nanoparticles (Kim, Haney et al.
2016). Herein, we attribute increased drug accumulation
to the adhesive proteins expressed on EVs surface, lead-
ing to the superior interactions with the cellular mem-
branes compared to liposomes.
Finally, a superior intracellular accumulation of the incor-
porated into EVs anticancer drugs in TNBC cell monocytes
was confirmed in confocal studies (Fig. 2 b). The incubation
of MDA-MB-231 cells with EV-PTX and EV-Dox resulted in
the considerable drug uiptake compared to liposomal-based
drug formulations. Of note, significant amount of Dox was
delivered to the target organelle, i.e. nuclei (Fig. 2 b).
Tumor Targeting and Biodistribution of EVs
in Orthotopic TNBC Mouse Models
First, tumor accumulation of fluorescently-labeled DID-EVs
was documented in nude mice with MDA-MB-231 solids
upon systemic administration (Figrue S5). Interesting, EVs
staining was more pronounced at the tumor periphery
(Figure S5 B) compared to tumor center (Figure S5 A). We
hypothesized that homogeneous intratumoral distribution of
EVs nanocarriers may be limited by high interstitial pressure
and dense stroma.
Next, we compared tumor accumulation of EVs and lipo-
somes using immunocompetent orthotopic TNBC model up-
on different routes of administration. To induce tumors
BALB/C mice were inoculated with T11 cells overexpressing
mCherry reporter protein (mCherry-T11), and 15 days later
when the tumors reached about 200 mm in diameter, the
tumor-bearing mice were injected through intravenous (i.v.),
or intraperitoneal (i.p.), or intratumoral (i.t.) routes with DID-
labeled EVs or liposomes. Four hours after injections, mice
were sacrificed, perfused; the tumors were sectioned on mi-
crotome and examined by confocal microscopy (Fig. 3).
Confocal images revealed, a substantial amount of EVs ad-
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Fig. 2 EV-mediated accumulation of Dox and PTX in TNBC cells
in vitro. EV-mediated accumulation of Dox and PTX in TNBC cells
in vitro. MDA-MB-231 cell monolayers were supplemented with the
selected optimal formulations of EV-Dox (pH 8.0, sonication), and EV-
PTX (sonication at RT) or the same amount of liposomes loaded with
Dox or fluorescently labeled PTX (7 × 1010 particles/mL) for 4 h, washed
×3 with PBS, and the amount of the accumulated drugs in the cells was
accessed by fluorescence. a: EVs facilitated drug accumulation in TNBC
cells at significantly greater levels compared to liposomes. **p < 0.005.
b: Confocal images confirmed the superior accumulation of PTX (green)
or Dox (red) in cancer cells when loaded into EVs. Nuclei were labeled
with DAPI (blue). The bar: 20 μm
solid T11 tumors and co-localized with the cancer cells (Fig. 3
a, c). The estimates for co-localization of EVs with mCherry-
T11 cells were 63.6 ± 2.1% and 48.4 ± 1.6% for of i.v. and i.p.
administration routes, respectively. In contrast, little if any
liposomes were delivered to the tumors followed by i.v. or
i.p. administration (Fig. 3 b, d). Of note, after direct i.t. injec-
tion both EVs and liposomes were found in the tumors (Fig. 3
e, f). Additional images for EVs and liposome biodistribution
in solid tumors are shown in Figures. S2, and S3, respectively.
Moreover, similar to liposomes, fluorescently-labeled poly-
mer-based nanocarriers (polystyrene nanoparticles, PS) also
showed limited distribution in TNBC tumors upon i.v. and
i.p. administration ( Figure S4). Of note, no difference in
EVs intratumoral distribution was found in T11 solids. The
obtained data clearly demonstrated the advantages EVs over
liposomes as drug nanocarriers suggesting that systemically
administered EVs can successfully reach solid tumors and
deliver their drug payload to target TNBC cells.


















Fig. 3 DID-labeled EVs target TNBC solid tumors in vivo. BALB/C
mice were orthotopically injected with 0.8 × 106 mCherry-T11 cells (here
green) in matrigel. 15 days later, mice were injected with DID-EVs (a, c,
e), or DID-liposomes (b, d, f) through i.v. (a, b), or i.p. (c, d), or i.t. (e, f)
route (1011 particles/100μL/mouse, here red). Four hours later, mice were
sacrificed, perfused, tumor sides were sliced, sectioned, mounted on
slides with DAPI staining (blue), and studied by confocal microscopy.
Considerable amount of EVs, but not liposomes was detected in TNBC
tumors upon i.v. and i.p. administration. A co-localization of EVs with
TNBC cells was manifested in yellow (a, c, e). The bar = 50 μm
Table 1 Cytotoxicity of
EV-PTX and EV-Dox Formulation IC,50, (μM)
1
EVs alone N/A
Dox 6.4 ± 0.7
Doxil 3.3 ± 0.05
EV-Dox 2.1 ± 0.03
Taxol 0.6 ± 0.03
EV-PTX 2.1 ± 0.03
1Data are shown as IC50 values in μM±
SD. Values are the mean of triplicate
experiments
Therapeutic Effect of EV-Based Formulations
against TNBC Tumors In Vitro and In Vivo
We selected optimized formulations of EV-Dox (pH 8, soni-
cation) and EV-PTX (sonication at RT) with the highest load-
ing efficiency, and examined their cytotoxicity in vitro using
MDA-MB-231 cells. Consistently with previous reports
(Kim, Haney et al. 2016, Kim, Haney et al. 2018), the incor-
poration of anticancer drugs into EVs did not significantly
alter drug IC50 compared to commercially available drug for-
mulations, Doxil and Taxol (Table 1), indicating that the in-
corporation of drugs into EVs does not decrease their ability to
reach their intracellular targets and eradicate cancer cells.
Finally, for the in vivo efficacy studies, we used an immu-
nodeficient (Fig. 4 a), and immunecompetent (Fig. 4 b)
orthotopic TNBC tumor models. For the former, nude mice
with establishedMDA-MB-231 solids were systemically (i.v.)
injected with the optimal EV-PTX formulation (sonication at
RT, 0.5 mg/kg), or the same dose of commercially available
PTX formulation, Taxol, or empty EVs or saline as a control
four times on day 1, 4, 7, and 9; and the tumor growth was
recorded until the first animal in control group injected with
saline reached an end point. A systemic administration of EV-
PTX caused significantly stronger suppression of tumor
growth (TI = 71%) compared to the same dose of commercial-
ly available PTX formulation, Taxol (TI = 29%). No signifi-
cant anticancer effect was found for sham EVs (without PTX,
TI = 21%).
Next, immunocompetent Balb/C mice with established
TNBC tumors were systemically (i.v.) injected with Dox in
saline (2.5 mg/kg/mouse), or the same dose of optimized EV-
Dox formulation (pH 8, sonication), or liposomal Dox
(Doxil), or saline as a control. The incorporation of Dox into
EVs resulted in significant inhibition of TNBC tumor growth
in immune competent mice BALB/C mice (Fig. 4 b).
Specifically, TI values were ca. 40%. In contrast, Dox alone
did not have any significant antitumor activity in T11 solids
(TI = 19%). Noteworthy, injections of control empty (naïve)
EVs without incorporated drugs did not slow down tumor
growth in mice with orthotopic TNBC tumors (Fig. 4 a, b).
Of note, liposomal Dox formulation also showed inhibition of
tumor growth in this animal model that was not significantly
different from EV-Dox inhibition effect. We hypothesized that
accordingly to biodistribution studies, T11 solids may have
relatively low-density stroma that allows deep penetration of
Dox released from nanocarriers (EVs and liposomes) to the
center of the tumor.
Discussion
The delivery of antineoplastic agents to cancer cells remains
one of the greatest challenges for the treatment of TNBC.
Several synthetic nanoformulations of small molecule anti-
cancer drugs and antioxidants are being developed for treat-
ment of TNBC (Greish et al. 2018, Krausz et al. 2018, Sorolla
et al. 2019, Valcourt et al. 2019). However, conventional
nanoparticles have limited biocompatibility, and normally
are cleared rapidly from the circulation by the MPS (Peng
et al. 2013). To address this problem, we developed a novel
drug delivery system that is based on natural vectors EVs for
the delivery of anticancer agents with different solubility in





































Fig. 4 EV-based formulations of
PTX and Dox suppress tumor
growth in orthotopic TNBC
mouse models. c: nude mice
bearing MDA-MB-231 solid tu-
mors, or b: Balb/C mice bearing
T11 solid tumors were injected on
days 1, 4, 7, and 9 (red arrows)
with: saline, or commercially
available drug nanoformulation
(Taxol or Doxil), or Dox in saline,
or drug incorporated into EVs
(EV-PTX or EV-Dox), and the
relative tumor weight (RW) ±
SEM, was determined for each
group (N = 7). EV-based formu-
lations of PTX and Dox showed
superior therapeutic efficacy
compared to Taxol (a), or Dox
alone (b), or saline-treated ani-
mals. *p < 0.05 compared to
Taxol or Dox-treated, and #p <
0.05 compared to saline-treated
animals
biological activity reflective of their origin, macrophages, spe-
cifically, target cancer cells in vivo.
Using EVs as drug delivery vehicles offers a number of
benefits over common drug administration regimens; howev-
er, there are some limitations and challenges that need to be
addressed. One of the major challenges is the efficient loading
of EVs without significant alterations to the structure and con-
tent of the EV membranes. To achieve favorable conditions
for drug loading, we developed a specific procedure wherein
the relatively tight and highly structured lipid bilayers are
reshuffled upon a mild sonication. One of the important con-
clusions regarding these evaluations is that a small molecule
anticancer drug should be relatively hydrophobic to incorpo-
rate into EVsmembranes. Thus, using pH that is close to pI for
Dox (i.e. decreasing charge of the molecule and increasing its
hydrophobicity) significantly improved Dox loading into
EVs. On the other hand, PTX is a highly hydrophobic com-
pound; therefore, the main challenge for the PTX incorpora-
tion is to provide a wide access of this drug to EVs mem-
branes. According to our studies, the incorporation of PTX
into EVs nanocarriers was more efficient when PTX was
added to EVs suspension in ethanol solution, compared to
PTX thin film. We hypothesized that the addition of the drug
to the bulk solution along with the small amount of ethanol
provided high local concentration of PTX, and at the same
time, caused a mild fluidization of EVs membranes resulting
in the efficient PTX incorporation. Another important finding
is that the temperature of the mixture drastically affects the
drug loading into EVs. Specifically, sonication EVs with PTX
at room temperature (with short periods of cooling down in
between the cycles) was more efficient that sonication on ice
that was kept for the continuous time (during sonication and
intermediate periods). Of note, Western blot analysis indicated
that EV-based drug formulations obtained by sonication retain
specific adhesive proteins in EVs membranes that are crucial
for their interaction with target cancer cells.
Regarding delivery of anticancer agents to TNBC cells,
EVs facilitated drug accumulation in cancer cells compared
to liposomal-based drug nanoformulations in vitro. This is in
agreement with a recent report regarding rapid cellular uptake
of doxorubicin loaded into EVs by electroporation and its re-
distribution from endosomes to the cytoplasm and nucleus in a
number of cultured and primary cell lines, when compared to
free Dox, or liposomal Dox (Schindler et al. 2019).
The most promising results were obtained in the mouse
TNBC models. Our data demonstrate a robust accumulation
and significant co-localization of systemically administered
EVs with TNBC cells upon different routes of administration,
including i.v., i.p., and i.t. administration. In contrast, little if
any liposomes or polymer-based nanoparticles were found in
TNBC solids upon i.v., and i.p. administration. Only i.t. route
allowed delivery of significant amount of these synthetic
nanocarriers to the tumors. To this end, we reported earlier
that macrophage-derived EVs inherited LFA1 protein
expressed on EVs membranes that may be responsible for
their preferential accumulation in cancer cells upon systemic
administration (Kim, Haney et al. 2016, Kim, Haney et al.
2018). The investigations of trafficking of EVs and their com-
ponents (loaded therapeutic agents, as well as EVs lipids, and
proteins, etc.) are on the way in our laboratory.
Finally, a systemic administration of EV-based formula-
tions of PTX and Dox resulted in the potent tumor growth
suppression in mice with TNBC solids, as compared to
Taxol or Dox treated animals, probably, due to the efficient
delivery of the incorporated into EVs drug to tumors.
Furthermore, low immunogenicity and high stability might
increase EVs time circulation in the blood (Gardai et al.
2005, Long and Beatty 2013, Kaur et al. 2014, Ha et al.
2016, Jiang and Gao 2017). In fact, it is known that EV-
mediated cell-to-cell communication is key in the battle be-
tween cancer and the immune system (Finn 2012). Thus,
Parolini et al. (Parolini et al. 2009) showed that EVs fusion
with target cells occurs more efficiently under acidic condi-
tions, implying that EVs may be taken up preferentially by
tumors (which have an acidic microenvironment) rather than
the surrounding healthy tissue.
Overall, all three mechanisms mentioned here are likely to
have significant impact on EV-based drug formulations anti-
cancer activity, i.e.: (i) efficient delivery of incorporated cargo
into target cancer cells, (ii) preferential accumulation in tumor
cells due to LFA1/ICAM1 interactions, and (iii) prolonged
circulation time in the blood. Further studies of the mechanism
of these superior antineoplastic effects are ongoing in our lab.
Using EVs as drug delivery vehicles takes advantage of their
natural carriage and extraordinary ability to interact with target
cells. It offers several benefits over common drug administration
regimens; however there are number of limitations and chal-
lenges that need to be addressed. One of the major challenges
is whether the sufficient number of these nanocarriers can be
generated (Nordin et al. 2015) to manufacture scalable and re-
producible lots. The reproducibility and consistency of the prod-
uct lots may be difficult to achieve as the starting material may
come from many different donors and thus possesses inherent
variability (Patel et al. 2005). As of today, the good manufactur-
ing procedures (GMP) have been developed in Industry and
Academia (Pachler et al. 2017, Mendt et al. 2018), such as
Wake Forest Institute for Regenerative Medicine labs (EVs
enriched with specific microRNAs). These efforts support more
than half a dozen clinical trials that have already demonstrated
feasibility and short-term safety of EVs administration
(Mentkowski et al. 2018). Specifically, EVs were purified from
monocyte cultures from 15 patients with advanced metastatic
melanoma. The GMP process allowed harvesting about 5 ×
1014 EVs MHC class II carriers (Mignot et al. 2006). In another
trial, a total of 40 patients with advanced colorectal cancer re-
ceived up to 2 × 1012 EVs weekly for 4 weeks (Dai et al. 2008).
The therapies were safe, feasible, and efficient in induction of
antigen-specific T lymphocyte response. A major effort is under-
way on clinical implementation of EV-based therapeutics, includ-
ing: (1) MolecuVax, Inc. (peptide/EVs technology); (2) Stem
Cell Medicine Ltd. (EVs for neurodegenerative diseases); (3)
Evox Therapeutics (EVs for Duchenne muscular dystrophy);
and (4) Jazz Pharmaceuticals Inc. (EVs for cancer). The cellular
origin for EVs varies from dendritic cells (Escudier et al. 2005,
Morse et al. 2005, Besse et al. 2016, Baghaei et al. 2018), retic-
ulocytes (Diaz-Varela et al. 2018), erythrocytes (Hafiane and
Daskalopoulou 2018), monocytes (Singhto et al. 2018), macro-
phages (Rice et al. 2018) to mesenchymal (Bobis-Wozowicz
et al. 2017, de Godoy et al. 2018, Ferreira and Gomes 2018)
and human iPSCs (Adamiak et al. 2018, Taheri et al. 2018).
Notably, EVs can be concentrated, lyophilized, and reconstituted
in aqueous solutions (Haney et al. 2015). Thus, quality control of
the lots is of paramount importance in order to ensure safety and
reproducibility. In summary, EVs offer many advantages over
other potential drug delivery systems, specifically: high stability,
low immunogenicity, ability to avoid accumulation and clearance
by mononuclear phagocytes, biocompatibility, extraordinary bi-
ological activity, and efficient drug transfer to target cells. These
biomimetic drug delivery systems that are capable of recognizing
and targeting cancer cells and inflammation, are one of the prom-
ising and competitive carriers for drug delivery, especially in case
of TNBC tumors with low expression of specific proteins for
targeted anticancer therapies available in clinic. In conclusion,
EVs promise an unparalleled efficacy in the treatment of many
life-threatening conditions, including those lacking effective
pharmacotherapy.
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